News Release Details
Opiant Pharmaceuticals Announces Appointment of Matthew Ruth as Chief Commercial Officer
Mr. Ruthled the highly successful launch and commercialization of the first FDA-approved nasal naloxone spray to treat opioid overdose
- He joins Opiant at a time when the Company is developing and moving towards potential commercialization of OPNT003, nasal nalmefene, a novel investigational treatment for opioid overdose
“We welcome Matt's highly relevant commercial leadership, insights and expertise as we continue to progress our lead candidate OPNT003, nasal nalmefene, through development for the treatment of opioid overdose," said
OPNT003, nasal nalmefene, is in development as a potent, rapid-onset, long-acting opioid antagonist for the treatment of opioid overdose. It is designed as a rescue medication that could be especially useful in treating overdose by high-potency synthetic opioids, such as fentanyl.
"With its development of the first FDA-approved naloxone nasal spray, Opiant helped transform the emergency treatment of opioid overdose, and I believe the company is positioned to make even further impact at a time when overdoses from potent illicit synthetic opioids are rampant in America," said Mr. Ruth. "I look forward to joining the team to build a commercial organization that will deliver on this promise and advance Opiant’s mission in addictions and drug overdose."
From 2015 until 2019,
Prior to his work in the opioid overdose space,
Earlier in his career,
About Opiant Pharmaceuticals, Inc.
This press release contains forward-looking statements, including statements for OPNT003’s potential as an opioid overdose reversal agent. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, and among other things, our ability to maintain cash balances and successfully commercialize or partner our product candidates currently under development. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. Additional factors that could materially affect actual results can be found in our Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on March 4, 2021, including under the caption titled "Risk Factors." These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.
For Media and Investor Inquiries:
Source: Opiant Pharmaceuticals, Inc.